GoKawiilHHS Tells FDA Not to Block Sales of Six Unapproved Peptide Drugs
HHS Secretary Robert F. Kennedy Jr. has directed the FDA to refrain from taking enforcement action against pharmacies selling six compounded peptides, including BPC-157, KPV and TB-500. The Associated Press reports the decision was made without input from FDA scientists, who generally opposed the change, and HHS says it is intended to expand patient choice while maintaining safety.
GoKawiil's interpretation of the reporting above, not reported fact.
The move could accelerate an already booming and loosely regulated market for peptides promoted by wellness influencers as metabolism, energy and recovery aids despite limited clinical evidence. Bypassing FDA scientific review raises questions, according to medical professionals cited by the AP, about consumer safety and oversight standards for compounded drugs sold outside traditional pharmacy channels.
- HHS instructed the FDA not to act against pharmacies selling six specific compounded peptides.
- The decision reportedly bypassed input from FDA scientists who opposed the policy.
- Scientists and medical professionals have raised safety and oversight concerns about the expanded access.
Source: futurism.com — Maggie Harrison Dupré, 2026-10-29
Published there as: “RFK Jr Opens the Floodgates on Experimental Peptides, Alarming Scientists”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.